Czebe Krisztina, Antus Balázs, Varga Marina, Csiszér Eszter
Országos Korányi Tbc- és Pulmonológiai Intézet III. Tüdobelosztály, Budapest.
Orv Hetil. 2008 Jan 20;149(3):99-109. doi: 10.1556/OH.2008.28233.
Lung transplantation has become an accepted therapeutic modality for end-stage diseases of the lungs and the pulmonary circulation. In the past two decades more than 20,000 lung transplantations were performed all over the world. Due to improvements in immunosuppressive regimens the mortality rate of severe acute rejections has decreased up to 2% in the first post-transplant year. By contrast, infections became the most common cause of morbidity and mortality after lung transplantation. It was reported that 21.2 and 40% of annual deaths are due to infections in the first 30 days and one year, respectively. In the first month 35-70% of transplant recipients develop bacterial pneumonia caused often by Gram-negative organisms especially by Pseudomonas species. All patients should receive prophylactic antibiotics after the operation, which are to be modified according to the resistance patterns of pathogens isolated from the donor lungs. In the early post-operative period, the frequency of invasive fungal (Aspergillus and Candida) and cytomegalovirus (CMV) infections appears to be less then 10% due to prophylactic amphotericin inhalation and systemic valganciclovir administration for 100 days. After withdrawing these drugs, these infections became more common. In the late post-transplant period, the development of bronchiolitis obliterans syndrome (BOS) may predispose to infections. BOS may be manifested in approximately 50% of patients 5 years post-transplant. Routinely or urgently performed screening tests (laboratory and radiological investigations, lung function tests, sputum culture, bronchoscopy) and specific treatments are of central importance in the management of infections. In this review we discuss the clinical manifestation, the diagnosis and the treatment possibilities of the most common pulmonary infections in lung transplant recipients.
肺移植已成为终末期肺部疾病和肺循环疾病公认的治疗方式。在过去二十年中,全球进行了超过20000例肺移植手术。由于免疫抑制方案的改进,严重急性排斥反应的死亡率在移植后第一年已降至2%。相比之下,感染成为肺移植后发病和死亡的最常见原因。据报道,分别有21.2%和40%的年度死亡病例在术后30天和一年内是由感染所致。在第一个月,35%-70%的移植受者会发生细菌性肺炎,通常由革兰氏阴性菌引起,尤其是假单胞菌属。所有患者术后均应接受预防性抗生素治疗,并根据从供体肺中分离出的病原体的耐药模式进行调整。在术后早期,由于预防性吸入两性霉素和全身给予缬更昔洛韦100天,侵袭性真菌(曲霉菌和念珠菌)和巨细胞病毒(CMV)感染的发生率似乎低于10%。停用这些药物后,这些感染变得更为常见。在移植后期,闭塞性细支气管炎综合征(BOS)的发生可能易导致感染。BOS可能在移植后5年约50%的患者中出现。常规或紧急进行的筛查试验(实验室和影像学检查、肺功能测试、痰培养、支气管镜检查)和特异性治疗在感染管理中至关重要。在本综述中,我们讨论了肺移植受者中最常见肺部感染的临床表现、诊断及治疗方法。